Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli.
Affiliation
Cancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.Issue Date
1990-06-15
Metadata
Show full item recordAbstract
A bacterial expression system which produces large amounts of the Epstein-Barr-virus-coded thymidine kinase has been developed and used to produce protein for Western blot analysis of a number of human antisera. Interestingly, only sera from nasopharyngeal carcinoma (NPC) patients had any detectable IgA antibody which reacted with the EBV TK. These findings provided the basis for ELISA tests using a crude lysate of the E. coli cells expressing the EBV TK as target antigen. Sera from NPC patients showed high levels of IgA reactive antibodies in this test while other sera did not.Citation
Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli. 1990, 45 (6):1028-32 Int. J. CancerJournal
International Journal of Cancer.DOI
10.1002/ijc.2910450608PubMed ID
2161795Type
ArticleLanguage
enISSN
0020-7136ae974a485f413a2113503eed53cd6c53
10.1002/ijc.2910450608